Clinical Trial Detail

NCT ID NCT03192345
Title A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sanofi
Indications

melanoma

colorectal adenocarcinoma

Advanced Solid Tumor

Therapies

Cemiplimab + SAR439459

SAR439459

Age Groups: adult senior

No variant requirements are available.